73%
jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
73%
jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
73%
jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
73%
jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Pacific Biosciences of California Inc
Suletud
SektorTervishoid
1.71 -12.31
Ülevaade
Aktsiahinna muutus
24h
Min
1.6800000000000002
Max
1.95
Sissetulek | 3.9M -38M |
|---|---|
Müük | -1.3M 38M |
Kasumimarginaal | -98.853 |
Töötajad | 575 |
EBITDA | 3.2M -32M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +23.08% upside |
Järgmine tulemuste avaldamine | 12. veebr 2026 |
|---|
Turukapital | -51M 622M |
|---|---|
Eelmine avamishind | 14.02 |
Eelmine sulgemishind | 1.71 |
Uudiste sentiment
By Acuity
26%
74%
52 / 352 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Bullish Evidence
Pacific Biosciences of California Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Pacific Biosciences of California Inc Prognoos
Hinnasiht
By TipRanks
23.08% tõus
12 kuu keskmine prognoos
Keskmine 2.4 USD 23.08%
Kõrge 3 USD
Madal 2 USD
Põhineb 5 Wall Streeti analüütiku instrumendi Pacific Biosciences of California Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
52 / 352 Pingereas Tervishoid
Uudiste sentiment
Languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Pacific Biosciences of California Inc
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Live chat